Skip to main content

Peer Review reports

From: Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study

Original Submission
3 Mar 2024 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
23 Mar 2024 Author responded Author comments - Fabio Canino
Resubmission - Version 3
23 Mar 2024 Submitted Manuscript version 3
9 Apr 2024 Reviewed Reviewer Report - Giorgio Mustacchi
18 Apr 2024 Reviewed Reviewer Report - Helena Earl
4 May 2024 Reviewed Reviewer Report
17 May 2024 Reviewed Reviewer Report
28 May 2024 Author responded Author comments - Fabio Canino
Resubmission - Version 4
28 May 2024 Submitted Manuscript version 4
7 Jun 2024 Reviewed Reviewer Report
8 Jun 2024 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
11 Jun 2024 Editorially accepted
15 Jun 2024 Article published 10.1186/s12885-024-12506-0

You can find further information about peer review here.

Back to article page